Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients. This study aimed to investigate the lifetime cost-effective value of IDegLira compared with its single component (Degludec or Liraglutide) and to explore the suitable annual cost of IDegLira if necessary.Methods: UKPDS OM2 was applied to determine the long-term quality-adjusted life years (QALYs) and total costs. The efficacy data that were inputted into the model were synthesized from 6 randomized clinical trials (RCTs) that directly assessed the clinical benefit of IDegLira and its components in the treatment of uncontrolled T2D patients. The economic results were examined by one-way sensi...
Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...
Item does not contain fulltextBACKGROUND: Addition of the GLP-1 receptor agonist liraglutide to insu...
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE...
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec ...
Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improve...
Introduction: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) ...
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin ...
Objective: To evaluate the long-term cost-effectiveness of dapagliflozin (a novel sodium- glucose co...
ObjectiveTo systematically estimate and compare the effectiveness and cost-effectiveness of the gluc...
OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...
<div><p>Background</p><p>We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor ...
We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 ...
Background: Diabetic nephropathy is a major microvascular complication and the main cause of end-sta...
Background: Diabetic nephropathy is a major microvascular complication and the main cause of end-sta...
To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in trea...
Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...
Item does not contain fulltextBACKGROUND: Addition of the GLP-1 receptor agonist liraglutide to insu...
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE...
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec ...
Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improve...
Introduction: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) ...
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin ...
Objective: To evaluate the long-term cost-effectiveness of dapagliflozin (a novel sodium- glucose co...
ObjectiveTo systematically estimate and compare the effectiveness and cost-effectiveness of the gluc...
OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...
<div><p>Background</p><p>We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor ...
We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 ...
Background: Diabetic nephropathy is a major microvascular complication and the main cause of end-sta...
Background: Diabetic nephropathy is a major microvascular complication and the main cause of end-sta...
To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in trea...
Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...
Item does not contain fulltextBACKGROUND: Addition of the GLP-1 receptor agonist liraglutide to insu...
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE...